DRD2 and early-onset autosomal dominant Alzheimer disease: These data sets targeted specific molecular targets involvedin Alzheimer’s disease (β-site amyloid precursor protein(AAP) cleaving enzyme 1, BACE1), inflammatory diseases (CC chemokinereceptor 5, CCR5), neurological diseases (dopamine D2 receptor, DRD2),cancer (epidermal growth factor receptors, EGFR), and liver disease(nuclear receptor subfamily 1 group H member 2, NR1H2).5